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Background: Clinical and laboratory studies have indicated that coinfection with hepatitis B virus (HBV) and
hepatitis C virus (HCV) can suppress one another, eliciting a dominant disease phenotype. To assess whether HBV
can influence the antiviral effect of treatment on HCV, we performed a meta-analysis to comparatively analyze the
response to interferon plus ribavirin treatment in patients with HBV/HCV coinfection and HCV mono-infection.
Methods: Published studies in the English-language medical literature that involved cohorts of HBV/HCV
coinfection and HCV mono-infection were obtained by searching Medline, Cochrane and Embase databases.
Studies that compared the efficacy of treatment with interferon plus ribavirin in HBV/HCV coinfection and HCV
mono-infection were assessed. End-of-treatment virological response (ETVR), sustained virological response (SVR),
HCV relapse rate, and alanine aminotransferase (ALT) normalization rate were compared between HBV/HCV
coinfection and HCV mono-infection patients.
Results: Five trials involving 705 patients were analyzed. At the end of follow-up serum ALT normalization rates in
patients with HCV mono-infection were significantly higher than in patients with HBV/HCV coinfection (odds ratio
(OR) = 0.56, 95% confidence interval (CI): 0.40–0.80, P = 0.001). The ETVR and SVR achieved in HBV/HCV coinfection
patients were comparable to those in HCV mono-infection patients (OR = 1.03, 95% CI: 0.37–2.82, P = 0.96 and
OR = 0.87, 95% CI: 0.62–1.21, P = 0.38, respectively). The rate of relapse for HCV or HCV genotype 1 was not
significantly different between HBV/HCV coinfection patients and HCV mono-infection patients (OR = 1.55, 95%
CI: 0.98–2.47, P = 0.06; HCV genotype 1: OR = 2.4, 95% CI: 1.17–4.91, P = 0.19).
Conclusions: Treatment with interferon and ribavirin achieves similar ETVR and SVR in HBV/HCV coinfection and
HCV mono-infection. HBV/HCV coinfection patients had distinctively lower end of follow-up serum ALT
normalization.
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Hepatitis B virus (HBV) and hepatitis C virus (HCV) are sig-
nificant human pathogens of global concern. Infection with
either hepatitis virus can lead to chronic liver disease, se-
verely degrading quality of life and eventually causing death.
The infection elicits a persistent host inflammatory re-
sponse, which is accompanied by activation of biomolecule
signaling cascades that can promote chronic hepatitis, liver
cirrhosis, and/or hepatocellular carcinoma (HCC) [1-3].
These two hepatotropic viruses share the same modes of
transmission and often appear as a coinfection in geo-
graphic locales where HBV or HCV is considered endemic
[4-6]. In Taiwan, 11% of patients with HBV–related
chronic liver disease also presented with positive immu-
noreactivity for anti-HCV antibody [5,7]; likewise, 12% of
the Taiwanese anti-HCV positive patients had detectable
levels of hepatitis B surface antigen (HBsAg) in their serum
[4]. In Italy, up to 40% of patients with chronic hepatitis B
(CHB) have been reported as anti-HCV positive [8]. More-
over, occult HBV infection has been described in patients
with chronic hepatitis C (CHC) [9,10].
Several clinical and laboratory studies have investi-
gated the potential interactions of HBV and HCV and
their concomitant affects on the immune response; these
studies have revealed that HBV and HCV are capable of
suppressing replication of one other in coinfection con-
ditions [11-14]. Clinically, patients with HBV/HCV coin-
fection have a much higher risk of developing cirrhosis,
hepatic failure, and HCC than patients with HBV or
HCV mono-infection [14-19].
The current gold standard treatment of CHC is a com-
bination pharmacotherapy using pegylated (PEG) inter-
feron (IFN) and ribavirin [20-22]. Interferon has also
been shown as an effective treatment for CHB [23,24];
however, interferon alone is not effective in clearing
HCV from patients with HBV/HCV coinfection [25-29].
The combination treatment strategy of interferon plus
ribavirin is more effective for HCV clearance in patients
with HBV/HCV coinfection, and current treatment
guidelines recommend this approach. However, the effi-
cacy of combination treatment in HBV/HCV coinfection
has yet to be definitively evidenced as equal to that in
HCV mono-infection [30-32]. To this end, we per-
formed a comparative analysis of the therapeutic efficacy
of interferon plus ribavirin reported from cohort studies
of patients with HBV/HCV coinfection and HCV mono-
infection by undertaking a meta-analysis according to
PRISMA (Transparent Reporting of Systematic Review
and Meta-analyses) criteria [33] (Additional file 1).
Methods
Literature search
Relevant studies were identified by searching the Med-
line, Embase, and Cochrane databases, using thefollowing medical subject headings: “hepatitis B virus
and hepatitis C virus coinfection”, “hepatitis B virus and
hepatitis C virus dual infection”, “interferon and riba-
virin”, and “antiviral therapy”. The scope of the search
was restricted to “human” and “English”. We included
all cohort studies. The search was carried out in March
2011, without a lower date limit for the search results.
The reference lists of all retrieved review articles were
manually searched to identify potentially relevant articles
missed by the computer search. We used only previously
published data, so approval from the ethics committee
was not required.
Inclusion and exclusion criteria
Inclusion criteria for the meta-analysis were as the fol-
lows: (1) cohort study design (each group sample size
>10); (2) study including an HBV/HCV coinfection
group and an HCV mono-infection group; and (3)
patients of two groups treated with interferon plus riba-
virin. Patient populations were excluded if they featured:
(1) coinfection with hepatitis A, D, or E virus, or human
immunodeficiency virus (HIV); (2) diagnosis of auto-
immune hepatitis, primary biliary cirrhosis, Wilson’s dis-
ease, decompensated cirrhosis, or overt hepatic failure;
(3) clinical evidence of HCC; (4) current or past history
of alcohol abuse (alcohol intake ≥20 g daily); or (5) use
of antiviral drugs or immunomodulatory drugs at any
time within the preceding six months. Any dataset for
which sufficient analytic information was not available
was also excluded from the meta-analysis.
Efficacy measures
The primary efficacy end-point was sustained virological
response (SVR), which was defined as the proportion of
patients with undetectable serum HCV-RNA for at least
24 weeks after treatment. Secondary end points were:
end-of-treatment virological response (ETVR), defined
as the proportion of patients with undetectable serum
HCV-RNA at the end of treatment; biochemical re-
sponse, defined as normalization of serum alanine ami-
notransferase (ALT); viral relapse, defined as the
proportion of patients with undetectable serum HCV-
RNA at the end of treatment but with detectable serum
HCV-RNA at follow-up; and viral interaction of HBV
and HCV in HCV/HBV coinfection patients.
Data extraction
Two authors (Liu and Sheng) independently evaluated
the retrieved studies according to the inclusion criteria
and performed data extraction. The following data were
extracted from each paper: (1) number of patients in the
study; (2) details of the study design; (3) patient charac-
teristics; (4) treatment doses and duration; and (5)
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were resolved by consensus.
Study quality
Quality of each study was independently assessed by the
same two authors (Liu and Sheng) according to the fol-
lowing high-quality features: (1) cohort studies designed
with case characteristics (clinical and/or demographic)
matched to controls; and (2) presence of a definitive list-
ing of inclusion and exclusion criteria for patients, along
with clear definitions of treatment response. When dis-
crepancies arose, a third party (Peng Hu) was consulted.
Statistical analysis
Meta-analysis was performed using Review Manager
Software 5.0 (Cochrane Collaboration, Oxford, United
Kingdom), according to recommendations of the manu-
facturer and the Quality of Reporting of Meta-analyses
(QUORUM) guidelines (DerSimonian R, Laird N, et al.
1986; Moher D, Cook DJ, et al. 2000). Statistical analysis
for dichotomous variables was carried out. Outcomes
were expressed as relative risks (RR) with 95% confi-
dence intervals (CI). If the value 1 was included in the
95% CI, the point estimate of the RR was considered to
have reached statistical significance (p < 0.05). The I-
squared (I2) statistic was used to measure the extent of
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Figure 1 Flow diagram of the meta-analysis study selection process.detected using the chi-square (X2) test. Since the X2 test
lacks power with few studies, we considered significant
heterogeneity having been met when both the X2 value
was within the 10% level of significance (P < 0.10) and
the I2 value exceeded 56%. In cases where significant
heterogeneity existed, the random effect model was used
for analysis, otherwise the fixed effect model was used.
Results
Search results and study characteristics
A total of 111 studies were identified and screened for
retrieval by using the strategy described above. After
screening the title or abstract, 91 studies were excluded
and 20 were retrieved and subjected to detailed evalu-
ation. By adhering to the inclusion criteria, 15 of those
studies were excluded. Finally, five cohort studies
[30,32,34-36] were chosen for inclusion in the meta-ana-
lysis, which comprised a total of 705 patients (Figure 1).
The basic characteristics of each of the five studies are
listed in Table 1. The overall population ethnicity was
Asian for all five studies, with one study [34] composed
of Chinese and four [30,32,34,36] composed of Taiwan-
ese. Patients entered the cohorts from August 2000 to
April 2007. The population size for each of the studies
ranged from 54 to 321. The mean age ranged from 44.9
[35] to 51.1 [32] years old. The percentage of males ran-
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IFN plus ribavirin regimen
Drugs Course, weeks Follow-up,
weeks






M: 9/37 46.4 ± 11.3 6.3 ± 1.3log10 M: 25/21 93 ± 18






M: 71/89 48.9 ± 10.5 2.29 ± 4.1 × 105 M: 110/50 126.1 ± 81.8
Chuang et al. [34] Taiwan Cohort C: 11/31 45.04 ± 10.7 5.38 ± 0.96log10 C: 21/21 2.64 ± 2.26log10 92.1 ± 73.0 IFN-α2b 24 24
M: 22/62 44.9 ± 11.2 5.60 ± 0.94log10 M: 48/36 141.1 ± 105.5
Hung et al. [30] Taiwan Cohort C: 14/22 48.8 ± 12.6 5.80 ± 1.10og10 C: 17/19 NR 125.8 ± 89.3 IFN-α2b 24 24
M: 28/44 48.3 ± 12.0 5.80 ± 1.10og10 M: 34/38 164.2 ± 139.9
Liu et al. [36] Taiwan Cohort C: 5/19 46.5 ± 13.2 2.4 ± 3.1 × 106 C: 14/7 1.3 ± 2.5 × 103 137.0 ± 81.0 IFN-α2a 24 24
M: 12/18 48.5 ± 9.4 1.9 ± 2.2 × 106 M: 17/13 177.0 ± 192.0
C HBV and HCV coinfection, M HCV mono-infection, NR not reported, UD not detectable by the real-time PCR assay.
Table 2 Outcomes of the clinical trials included in the meta-analysis
Study Sample
size (n)
HCV genotype (n) End of treatment End of follow-up
HCV ETVR (n) ALT
normalization
(n)





















C: 50 30 20 46 27 19 NR 27 12 15 19 15 4 NR
M: 46 25 21 32 14 18 NR 26 11 15 6 3 3 NR
Liu et al.
[32]
C: 161 97 64 138 82 56 NR 123 70 53 15 12 3 103
M: 160 110 50 141 95 46 NR 127 85 42 14 10 4 122
Chuang
et al. [34]
C: 42 21 21 NR NR NR NR 29 10 19 NR NR NR 23
M: 84 48 36 NR NR NR NR 54 39 15 NR NR NR 51
Hung et al.
[30]
C: 36 17 19 33 NR NR 24 25 10 15 8 NR NR 20
M: 72 34 38 68 NR NR 66 51 18 33 17 NR NR 52
Liu et al.
[36]
C: 24 14 7 16 10 6 12 9 3 6 7 NR NR 9
M: 30 17 13 25 NR NR 23 18 NR NR 5 NR NR 18














Figure 2 Comparison of the ALT normalization rates achieved at the end of follow up in HBV/HCV coinfection and HCV mono-infection
patients.
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copies/mL. Patients in three of the studies [30,34,36]
were treated with conventional interferon and ribavirin,
patients in the other two studies [32,35] were treated
with PEG-IFN (having a longer half-life) and ribavirin.
Outcomes of the clinical trials included in the meta-
analysis are presented in Table 2.
Comparison of serum ALT normalization rates achieved in
HBV/HCV coinfection patients and HCV mono-infection
patients
Four of the studies [30,32,34,36] reported end of follow-
up ALT normalization. Meta-analysis revealed that
patients with HBV/HCV coinfection have lower serum
ALT normalization than those with HCV mono-
infection at the end of follow-up (P = 0.001; Figure 2).
ALT normalization at the end of treatment in coinfec-
tion groups was also lower than in the HCV mono-
infection groups (P = 0.04; Figure 3).
Comparison of ETVR and SVR of HCV achieved in HBV/
HCV coinfection patients and HCV mono-infection
patients
The ETVR rate was similar between HBV/HCV coinfec-
tion groups and HCV mono-infection groups at the end
of treatment (85.98% vs. 86.36%, P = 0.96). Morover,
there was no significant difference in the SVR rate be-
tween the two groups at the end of follow-up (68.05%
vs. 70.41%, P = 0.38). Detailed information can be found
in Table 3.Figure 3 Comparison of the ALT normalization rates achieved at the
infection patients.Comparison of the relapse of HCV between HBV/HCV
coinfection and HCV mono-infection
The relapse of HCV rate was similar between HBV/HCV
coinfection groups and HCV mono-infection groups at
the end of follow-up (18.15% vs. 13.64%, P = 0.06). The
relapse of rate of HCV was also analyzed according to
HCV genotype 1 and HCV non-genotype 1 (Table 3).
The relapse of rates in both HCV genotype groups were
similar between the HBV/HCV coinfection groups and
HCV mono-infection groups at the end of follow-up
(HCV genotype 1: 21.26% vs. 9.62%, P = 0.19; HCV non-
genotype 1: 8.33% vs. 9.86%, P = 0.85) (Table 3).
Viral interaction of HBV and HCV in HCV/HBV coinfection
patients
All five [30,32,34-36] of the studies reported data for the
HBV DNA level at baseline and at the end of follow-up
in HBV/HCV coinfection patients. In addition, data for
the HBV DNA resurgence in patients with and without
HCV SVR were reported (Table 4). The rate of HBV
DNA resurgence in HBV/HCV coinfection patients with
HCV SVR was significantly higher than in those with-
out HCV SVR (OR = 3.36, 95% CI: 1.35–8.38, P = 0.009,
Figure 4).
Discussion
Several reports have revealed that HBV and HCV are
capable of suppressing replication of each other in
coinfection conditions. Dominant roles for both HCV
and HBV have been suggested by some investigatorsend of treatment in HBV/HCV coinfection and HCV mono-
Table 3 Pooled effect of HBV/HCV coinfection studies with HCV mono-infection control studies
Effects HBV/HCV HCV Effect size Heterogeneity
Studies (n) Sample size Events Sample size Events OR(95% CI) P I2 P
ETVR 4 271 233 308 266 1.03(0.37-2.82) 0.96 69% 0.02
SVR 5 313 213 392 276 0.87(0.62-1.21) 0.38 0% 0.61
HCV relapse 4 270 49 308 42 1.55(0.98-2.47) 0.06 47% 0.13
HCV genotype 1 relapse 2 127 27 135 13 2.4(1.17-4.91) 0.19 74% 0.05
HCV non-genotype 1 relapse 2 84 7 71 7 0.9(0.3-2.71) 0.85 0% 0.4o
OR odds ratio.
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HBV DNA was not always detectable in patients with
HBV/HCV coinfection, and that the rate of HBV DNA
resurgence in HBV/HCV coinfection patients with HCV
SVR was significantly higher than in those without
HCV SVR (31.11% vs. 11.29%, P = 0.009). These findings
are consistent with the idea that patients with HBV/
HCV coinfection show a large spectrum of virological
profiles. It is possible that dominance of HBV or HCV
may alternate at different periods during the infection.
Thus, we speculate that one of the viruses in patients
with HBV/HCV coinfection is capable of exerting its
particular pathogenic role and masking or silencing that
of the other virus. Moreover, once the dominant virus
becomes suppressed by treatment, the other may have a
tendency towards reactivation. This type of robust activ-
ity elicited by one virus can explain the increased sever-
ity of disease observed in patients with HBV/HCV
coinfection, as opposed to that in patients with mono-
infection of either of the two viruses.
The most commonly used clinical therapy to treat ei-
ther HBV or HCV is interferon, usually administered as
a subcutaneous injection. This drug was developed
based upon the normal host antiviral and immunomo-
dulatory actions that target invading viral pathogens
for destruction and clearance. Previous studies have
shown that patients with HCV mono-infection respond








Yu et al. [35] China 50 4 46
Liu et al. [32] Taiwan 161 76 85
Chuang et al. [34] Taiwan 42 16 26
Hung et al. [30] Taiwan 36 18 18
Liu et al. [36] Taiwan 24 20 4
NA not available, VR virological response (undetectable HBV DNA).supplemented with the nucleoside analogue ribavirin)
than to interferon monotherapy (SVR of 43% vs. 10%)
[27,29,37,38]. Moreover, patients with CHB treated
with conventional interferon achieved an SVR of 35%
[28], and use of PEG-IFN achieves an even higher
SVR in patients with CHB and CHC [39,40]. To date,
interferon has been the most studied pharmacologic
agent for treatment of HBV/HCV coinfected patients,
because of its proven activity against both viruses. The
efficacy of combination treatment with interferon plus
ribavirin in HBV/HCV coinfection patients has been
assessed in various studies [41,42], but very few studies
to date have comparatively analyzed HBV/HCV coin-
fection and HCV mono-infection, and the conclusions
have been largely discordant [30-32]. Liu et al. [35]
reported that the efficacy of combination therapy with
PEG-IFN and ribavirin was similar between HBV/HCV
coinfected and HCV monoinfected patients. However,
another study [34] showed that the HBV/HCV coin-
fected patients had higher ETVR and relapse rates than
monoinfected patients.
Our meta-analysis confirmed that the combination
treatment approach, with either conventional interferon
or PEG-IFN plus ribavirin, achieved comparable ETVR
and SVR in patients with HBV/HCV coinfection and
those with HCV mono-infection. Our analysis also
showed that patients with HBV/HCV coinfection were
at similar risk of HCV relapse to those with HCVted patients









HBV VR Overall HCV SVR Non- HCV
SVR
27 23 4 11 9 2
123 38 38 17 NA NA
29 13 5 14 13 1
25 11 3 6 4 2
9 15 6 4 2 2
Figure 4 Comparison of the HBVDNA resurgence HCV SVR groups and HCV non-SVR groups in HBV/HCV coninfection patients.
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genotype 1 or HCV non-genotype 1. However, combin-
ation treatment achieved higher ALT normalization in
HCV mono-infection patients than in those with HBV/
HCV coinfection by the ends of both treatment and fol-
low-up. According to the finding that eradication of one
hepatitis virus in patients with HBV/HCV coinfection
may lead to increased titer of the other, we speculate
that the resurgence of HBV might account for the per-
sistent hepatitis activity after the clearance of HCV.
Therefore, examination of HBV antigens and HCV repli-
cation in the liver compartment is required to confirm
this hypothesis.
These findings may provide insights into why the ALT
normalization rate in patients with HBV/HCV coinfec-
tion was lower than that in patients with HCV mono-
infection. Yet undefined viral interactions and their
impacts on treatment efficacy (for example, producing
similar ETVR and SVR but lower ALT normalization)
may explain the suppressive effect of HBV on HCV that
has been observed in HBV/HCV coinfected patients.
Once the dominant HBV becomes suppressed by IFN-
based therapy, coinfected patients may experience HCV
reactivation and manifest HCV-specific symptoms [21].
Therefore, clinicians should exercise caution when treat-
ing coinfected patients with combination therapy (the
combination of PEG-IFN and ribavirin being the pre-
ferred strategy), and perform careful follow-up with sys-
tematic supervision. Larger scale studies should be
carried out to determine whether prolonging the course
of antiviral treatment in patients with HBV/HCV coin-
fection will increase the risk of ALT normalization.
There are several limitations to our meta-analysis that
should be considered prior to generalization of our find-
ings. First, these five studies were composed exclusively
of individuals of Asian descent. Second, conclusions
were made based upon sub-analyses using calculated
p-heterogeneity values. Third, the studies were not iden-
tical in the administered doses of interferon and ribavirin,
types of interferon administered, or course of treatment;
these differences in study design may explain the statis-
tical heterogeneity. Fourth, the data of HCV relapse and
ALT normalization in genotype 1 and non-genotype 1infected patients were unavailable in some studies, which
may have affected the accuracy of this meta-analysis.
In conclusion, the results of our meta-analysis demon-
strate that combination treatment with interferon plus
ribavirin achieves similar ETVR and SVR in HBV/HCV
coinfection patients and HCV mono-infection patients.
However, HBV/HCV coinfection patients achieve signifi-
cantly lower ALT normalization and are at significantly
higher risk of relapse. The combination of PEG-IFN and
ribavirin is more effective than that of conventional
interferon and ribavirin for both coinfection and mono-
infection.Additional file
Additional file 1: PRISMA 2009 Checklist.
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